{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:31:24Z","timestamp":1793881884460,"version":"4.7.0"},"reference-count":223,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The recent advancement of mRNA technology has opened new therapeutic avenues for treating hematologic malignancies, offering innovative approaches to enhance existing immunotherapies. This review examines the expanding role of\n                    <jats:italic>in vitro<\/jats:italic>\n                    transcribed (IVT)-mRNA-based platforms in hemato-oncology, focusing on key areas: monoclonal antibody production, bispecific antibody development, and CAR-T cell engineering. Unlike conventional biologics, mRNA allows for\n                    <jats:italic>in vivo<\/jats:italic>\n                    expression of therapeutic proteins, reducing manufacturing complexity and expanding access through scalable, cell-free synthesis. IVT-mRNA-encoded monoclonal and bispecific antibodies can overcome limitations such as short half-life and the need for continuous infusion, while enabling innovations like Fc silencing, protease-activated masking, and combinatorial immunotherapies. In CAR-T cell therapy, IVT-mRNA provides transient, safer alternatives to viral vector-based approaches and facilitates emerging strategies such as\n                    <jats:italic>in vivo<\/jats:italic>\n                    CAR programming and IVT-mRNA vaccine-like boosters. Despite these advantages, challenges remain, including delivery precision, durability of therapeutic effects, and limited clinical trial success. Beyond therapeutic mechanisms, the integration of bioinformatics and AI in IVT-mRNA design is accelerating the development of personalized and efficient cancer treatments. Overall, mRNA technology is redefining immunotherapy in hematology and holds the potential to broaden access to advanced treatments globally.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1680071","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:15Z","timestamp":1761111135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Incorporating mRNA therapeutics into biological treatments of hematologic malignancies"],"prefix":"10.3389","volume":"16","author":[{"given":"Jaromir","family":"Hunia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaromir","family":"Tomasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Czerwik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmida Sadat","family":"Pezeshki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Nowis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907","article-title":"Acute lymphoblastic leukemia","volume":"339","author":"Pui","year":"1998","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.07.005","article-title":"Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical implications of genetic mutations in myelodysplastic syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic Malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3907","article-title":"Haematological Malignancies: at the forefront of immunotherapeutic innovation","volume":"15","author":"Bachireddy","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2307187","DOI":"10.1080\/21645515.2024.2307187","article-title":"Recent progress in mRNA cancer vaccines","volume":"20","author":"Yao","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(61)80072-7","article-title":"Genetic regulatory mechanisms in the synthesis of proteins","volume":"3","author":"Jacob","year":"1961","journal-title":"J Mol Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-coV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B","volume":"386","author":"Andrews","year":"2022","journal-title":"1.1.529) Variant N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J Control Release"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132505","article-title":"5'-triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.07.009","article-title":"Innate immune response to viral infection","volume":"43","author":"Koyama","year":"2008","journal-title":"Cytokine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O'Brien","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307798120","article-title":"Recent advances in nanoparticulate RNA delivery systems","volume":"121","author":"Witten","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01679","article-title":"Design of Ionizable Lipids To Overcome the Limiting Step of Endosomal Escape: Application in the Intracellular Delivery of mRNA, DNA, and siRNA","volume":"59","author":"Habrant","year":"2016","journal-title":"J Med Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2500From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000724","article-title":"Cutting edge: Cytosolic bacterial DNA activates the inflammasome via Aim2","volume":"185","author":"Warren","year":"2010","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2010.11.003","article-title":"Regulation of innate immunity through RNA structure and the protein kinase PKR","volume":"21","author":"Nallagatla","year":"2011","journal-title":"Curr Opin Struct Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx135","article-title":"N1-methyl-pseudouridine in mRNA enhances translation through eIF2\u03b1-dependent and independent mechanisms by increasing ribosome density","volume":"45","author":"Svitkin","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.54","article-title":"Design of an optimized wilms' Tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo","volume":"2","author":"Benteyn","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","article-title":"HPLC purification of in vitro transcribed long RNA","volume":"969","author":"Weissman","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1021\/acsnanoscienceau.2c00062","article-title":"Recent advances in site-specific lipid nanoparticles for mRNA delivery","volume":"3","author":"Xu","year":"2023","journal-title":"ACS Nanosci Au"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c08353","article-title":"Lipid nanoparticle-based delivery system-A competing place for mRNA vaccines","volume":"9","author":"Zhang","year":"2024","journal-title":"ACS Omega"},{"key":"B50","doi-asserted-by":"publisher","first-page":"102520","DOI":"10.1016\/j.omtn.2025.102520","article-title":"Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers","volume":"36","author":"Dietmair","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28745","article-title":"Anti-\u03b22M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity","volume":"135","author":"Zhang","year":"2014","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13265","article-title":"Antibody-mediated phagocytosis in cancer immunotherapy","volume":"319","author":"Van Wagoner","year":"2023","journal-title":"Immunol Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape","volume":"114","author":"Jain","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1990.50","article-title":"Development of human anti-murine antibody (HAMA) response in patients","volume":"68","author":"Tjandra","year":"1990","journal-title":"Immunol Cell Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1997.tb00466.x","article-title":"Anti-murine antibody response to mouse monoclonal antibodies in cancer patients","volume":"88","author":"Sakahara","year":"1997","journal-title":"Jpn J Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-540-73259-4_4","article-title":"Human monoclonal antibodies from transgenic mice","volume":"181","author":"Lonberg","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J BioMed Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(85)90144-9","article-title":"Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID)","volume":"85","author":"Ware","year":"1985","journal-title":"J Immunol Methods"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0570","article-title":"U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab","volume":"16","author":"Lemery","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0084","article-title":"Obinutuzumab for the treatment of indolent lymphoma","volume":"12","author":"Edelmann","year":"2016","journal-title":"Future Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/07853890802698842","article-title":"Challenges in monoclonal antibody-based therapies","volume":"41","author":"Samaranayake","year":"2009","journal-title":"Ann Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.11.008","article-title":"Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo vadis","volume":"111","author":"Jiskoot","year":"2022","journal-title":"J Pharm Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: Strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev"},{"key":"B74","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12967-023-04553-1","article-title":"Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy","volume":"21","author":"Zhao","year":"2023","journal-title":"J Transl Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018961","article-title":"Advancing mRNA technologies for therapies and vaccines: An African context","volume":"13","author":"Kairuz","year":"2022","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn1902","article-title":"The translational gap for gene therapies in low- and middle-income countries","volume":"16","author":"Doxzen","year":"2024","journal-title":"Sci Transl Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13020112","article-title":"Investment opportunities for mRNA technology in low- and middle-income countries: key findings and future perspectives","volume":"13","author":"Abreu","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1038\/s41467-018-06508-3","article-title":"Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection","volume":"9","author":"Tiwari","year":"2018","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"B83","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov Today"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.04.001","article-title":"Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion","volume":"399","author":"Johnson","year":"2010","journal-title":"J Mol Biol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/jmbi.1999.3156","article-title":"Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics","volume":"293","author":"Kipriyanov","year":"1999","journal-title":"J Mol Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological Malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207276","article-title":"Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.htct.2023.06.006","article-title":"All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia","volume":"46","author":"Mirfakhraie","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.791","article-title":"HER2\/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities","volume":"12","author":"Chu","year":"2022","journal-title":"Clin Transl Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000464","article-title":"A novel fc-engineered anti-HER2 bispecific antibody with enhanced antitumor activity","volume":"46","author":"Mohammadi","year":"2023","journal-title":"J Immunother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \"less-is-more\" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"MAbs"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"15521","DOI":"10.1038\/s41598-017-15748-0","article-title":"Rapid purification of human bispecific antibodies via selective modulation of protein A binding","volume":"7","author":"Zwolak","year":"2017","journal-title":"Sci Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00870-5","article-title":"An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies","volume":"54","author":"Ko","year":"2022","journal-title":"Exp Mol Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1210747","article-title":"Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding","volume":"8","author":"Dav\u00e9","year":"2016","journal-title":"MAbs"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259036","article-title":"Mesothelin\/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues","volume":"62","author":"Suurs","year":"2021","journal-title":"J Nucl Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2167189","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"MAbs"},{"key":"B118","doi-asserted-by":"publisher","first-page":"104958","DOI":"10.1016\/j.isci.2022.104958","article-title":"Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity","volume":"25","author":"Hangiu","year":"2022","journal-title":"iScience"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002428","article-title":"Novel anti-4-1BB\u00d7PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade","volume":"9","author":"Jeong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-020-16838-w","article-title":"Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody","volume":"11","author":"Geiger","year":"2020","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B123","doi-asserted-by":"publisher","first-page":"100961","DOI":"10.1016\/j.xcrm.2023.100961","article-title":"A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological Malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell Rep Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s44228-022-00023-5","article-title":"Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA\/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma","volume":"5","author":"Plesner","year":"2023","journal-title":"Clin Hematol Int"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050355","article-title":"Bispecific antibodies: A review of development, clinical efficacy and toxicity in B-cell lymphomas","volume":"11","author":"Salvaris","year":"2021","journal-title":"J Pers Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14062","article-title":"Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.2174\/138161208786369786","article-title":"Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use","volume":"14","author":"Calogiuri","year":"2008","journal-title":"Curr Pharm Des"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.02.008","article-title":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","volume":"178","author":"Park","year":"2023","journal-title":"Lung Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"B136","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","article-title":"Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1038\/bcj.2015.68","article-title":"T-cell ligands modulate the cytolytic activity of the CD33\/CD3 BiTE antibody construct, AMG 330","volume":"5","author":"Laszlo","year":"2015","journal-title":"Blood Cancer J"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13854","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGF\u03b2 inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1\/1b study","volume":"17","author":"Baranda","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen biTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2230888","DOI":"10.1080\/07853890.2023.2230888","article-title":"Blinatumomab as salvage therapy in patients with relapsed\/refractory B-ALL who have failed\/progressed after anti-CD19-CAR T therapy","volume":"55","author":"Qi","year":"2023","journal-title":"Ann Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104803","article-title":"Challenges facing CAR T-cell immunotherapy in multiple myeloma","volume":"104803","author":"Ouyang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41467-021-21445-4","article-title":"Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation","volume":"12","author":"Arenas","year":"2021","journal-title":"Nat Commun"},{"key":"B152","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1261070","article-title":"Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy","volume":"14","author":"Penny","year":"2023","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci Transl Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1494206","article-title":"Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation","volume":"15","author":"Hangiu","year":"2024","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455019","article-title":"Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B159","doi-asserted-by":"publisher","first-page":"e2304378","DOI":"10.1002\/smll.202304378","article-title":"In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007421","article-title":"Materials for improving immune cell transfection","volume":"33","author":"Kumar","year":"2021","journal-title":"Adv Mater"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01073-7","article-title":"Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway","volume":"8","author":"An","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211\u201301 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1182\/blood.V130.Suppl_1.1359.1359","article-title":"Treating relapsed\/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells","author":"Cummins","year":"2017","journal-title":"ASH 59th Annu Meeting; Atlanta USA: Blood;"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J Comput Chem"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2020-0191","article-title":"HeroMDAnalysis: an automagical tool for GROMACS-based molecular dynamics simulation analysis","volume":"13","author":"Rawat","year":"2021","journal-title":"Future Med Chem"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1107\/S2052252521011891","article-title":"Modeling a unit cell: crystallographic refinement procedure using the biomolecular MD simulation platform Amber","volume":"9","author":"Mikhailovskii","year":"2022","journal-title":"IUCrJ"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki376","article-title":"JCat: a novel tool to adapt codon usage of a target gene to its potential expression host","volume":"33","author":"Grote","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"B177","doi-asserted-by":"publisher","first-page":"17617","DOI":"10.1038\/s41598-020-74091-z","article-title":"Codon optimization with deep learning to enhance protein expression","volume":"10","author":"Fu","year":"2020","journal-title":"Sci Rep"},{"key":"B178","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/1471-2105-8-316","article-title":"Versatile annotation and publication quality visualization of protein complexes using POLYVIEW-3D","volume":"8","author":"Porollo","year":"2007","journal-title":"BMC Bioinf"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and Autodock\/Vina","volume":"24","author":"Seeliger","year":"2010","journal-title":"J Comput Aided Mol Des"},{"key":"B180","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12938-021-00897-1","article-title":"COMSOL Multiphysics\u00ae modelling of oxygen diffusion through a cellulose nanofibril conduit employed for peripheral nerve repair","volume":"20","author":"Towne","year":"2021","journal-title":"BioMed Eng Online"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann Hematol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"7451","DOI":"10.1182\/blood-2024-199992","article-title":"Assessing lipid nanoparticle RNA delivery including CRISPR-cas9 based therapy to bone marrow cells with emphasis on leukemic blasts-a proof-of-principle study","volume":"144","author":"Soerensen","year":"2024","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B184","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12967-025-06924-2","article-title":"Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"B186","doi-asserted-by":"publisher","first-page":"lqaa090","DOI":"10.1093\/nargab\/lqaa090","article-title":"Machine learning a model for RNA structure prediction","volume":"2","author":"Calonaci","year":"2020","journal-title":"NAR Genom Bioinform"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-4196-5_7","article-title":"Beyond alphaFold2: the impact of AI for the further improvement of protein structure prediction","volume":"2867","author":"Genc","year":"2025","journal-title":"Methods Mol Biol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"109845","DOI":"10.1016\/j.compbiomed.2025.109845","article-title":"RNA structure prediction using deep learning - A comprehensive review","volume":"188","author":"Chaturvedi","year":"2025","journal-title":"Comput Biol Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1445794","article-title":"Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects","volume":"14","author":"Kaur","year":"2024","journal-title":"Front Oncol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40364-022-00410-3","article-title":"Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia","volume":"10","author":"Liu","year":"2022","journal-title":"biomark Res"},{"key":"B191","doi-asserted-by":"publisher","first-page":"100996","DOI":"10.1016\/j.jpha.2024.100996","article-title":"Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost\/Bayesian method and ensemble model approaches","volume":"14","author":"Maharjan","year":"2024","journal-title":"J Pharm Anal"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1109\/JBHI.2024.3483316","article-title":"Interpretable dynamic directed graph convolutional network for multi-relational prediction of missense mutation and drug response","volume":"29","author":"Gao","year":"2025","journal-title":"IEEE J BioMed Health Inform"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3389\/fncom.2020.580632","article-title":"DNNBrain: A unifying toolbox for mapping deep neural networks and brains","volume":"14","author":"Chen","year":"2020","journal-title":"Front Comput Neurosci"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae262","article-title":"Unveil cis-acting combinatorial mRNA motifs by interpreting deep neural network","volume":"40","author":"Zeng","year":"2024","journal-title":"Bioinformatics"},{"key":"B195","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/acs.accounts.1c00621","article-title":"Machine learning for designing next-generation mRNA therapeutics","volume":"55","author":"Castillo-Hair","year":"2022","journal-title":"Acc Chem Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/frai.2025.1620572","article-title":"Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow","volume":"8","author":"Elfatimi","year":"2025","journal-title":"Front Artif Intell"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr8470","article-title":"Deep generative models design mRNA sequences with enhanced translational capacity and stability","author":"Zhang","year":"2025","journal-title":"Science"},{"key":"B198","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00216","article-title":"Coarse-grained simulation of mRNA-loaded lipid nanoparticle self-assembly","volume":"21","author":"Grzetic","year":"2024","journal-title":"Mol Pharm"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-4079-1_8","article-title":"gRNAde: A geometric deep learning pipeline for 3D RNA inverse design","volume":"2847","author":"Joshi","year":"2025","journal-title":"Methods Mol Biol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s43588-024-00720-6","article-title":"Deep generative design of RNA aptamers using structural predictions","volume":"4","author":"Wong","year":"2024","journal-title":"Nat Comput Sci"},{"key":"B202","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41592-024-02543-9","article-title":"RNA-Puzzles Round V: blind predictions of 23 RNA structures","volume":"22","author":"Bu","year":"2025","journal-title":"Nat Methods"},{"key":"B203","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s42003-023-05525-3","article-title":"Enhancing alphafold-multimer-based protein complex structure prediction with MULTICOM in CASP15","volume":"6","author":"Liu","year":"2023","journal-title":"Commun Biol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1022268103136","article-title":"Myeloma and race: a review of the literature","volume":"22","author":"Benjamin","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.focus.2022.100041","article-title":"Preventive behaviors among leukemia and lymphoma cancer survivors: results from the 2020 behavioral risk factor surveillance system survey","volume":"2","author":"Coughlin","year":"2023","journal-title":"AJPM Focus"},{"key":"B207","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J BioMed Sci"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00328-2","article-title":"Vaccine apartheid: global cooperation and equity","volume":"399","author":"Bajaj","year":"2022","journal-title":"Lancet"},{"key":"B209","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41562-022-01304-y","article-title":"Developing countries can make the mRNA vaccines they need","volume":"6","author":"Prabhala","year":"2022","journal-title":"Nat Hum Behav"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1429265","article-title":"Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19","volume":"12","author":"Iqbal","year":"2024","journal-title":"Front Public Health"},{"key":"B211","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41541-024-01019-3","article-title":"Mapping global public perspectives on mRNA vaccines and therapeutics","volume":"9","author":"Xu","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.27.601046","article-title":"circPCMTD1: A protein-coding circular RNA that regulates DNA damage response in BCR\/ABL -positive leukemias","author":"Papaioannou","year":"2024","journal-title":"bioRxiv"},{"key":"B213","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40364-022-00392-2","article-title":"Roles of circRNAs in hematological Malignancies","volume":"10","author":"Deng","year":"2022","journal-title":"biomark Res"},{"key":"B214","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-020-00976-1","article-title":"The functions and clinical significance of circRNAs in hematological Malignancies","volume":"13","author":"Zhou","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.81","article-title":"CircRNAs in hematopoiesis and hematological Malignancies","volume":"6","author":"Bonizzato","year":"2016","journal-title":"Blood Cancer J"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00649","article-title":"Global increase in circular RNA levels in myotonic dystrophy","volume":"10","author":"Czubak","year":"2019","journal-title":"Front Genet"},{"key":"B217","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B218","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1038\/s41467-025-61775-1","article-title":"Chemical circularization of in vitro transcribed RNA for exploring circular mRNA design","volume":"16","author":"Wasinska-Kalwa","year":"2025","journal-title":"Nat Commun"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01393-0","article-title":"Engineering circular RNA for enhanced protein production","volume":"41","author":"Chen","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"105638","DOI":"10.1016\/j.ebiom.2025.105638","article-title":"Unlocking the potential of circular RNA vaccines: a bioinformatics and computational biology perspective","volume":"114","author":"Liu","year":"2025","journal-title":"EBioMedicine"},{"key":"B221","doi-asserted-by":"publisher","first-page":"11688","DOI":"10.1038\/s41598-019-48133-0","article-title":"Exosomal miR-16-5p as a target for Malignant mesothelioma","volume":"9","author":"Munson","year":"2019","journal-title":"Sci Rep"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201906_18192","article-title":"MicroRNA-16 inhibits the proliferation, migration and invasion of non-small cell lung carcinoma cells by down-regulating matrix metalloproteinase-19 expression","volume":"23","author":"Tian","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08842-1","article-title":"Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines","volume":"641","author":"Krawczyk","year":"2025","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:17Z","timestamp":1761111137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":223,"alternative-id":["10.3389\/fimmu.2025.1680071"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1680071","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1680071"}}